Treatment of Erythrasma: A double-blinded randomized controlled trial on clinical application of Clotrimazole and Sertaconazole

Background and Objective: Erythrasma is a mild superficial skin infection, developed by a group of aerobic microorganisms called Corynebacterium Minutissimum. It is proposed that topical Clotrimazole and Sertaconazole may be effective in the treatment of Erythrasma. So the aim of this study is to compare the effect of Clotrimazole and Sertaconazole on Erythrasma . Materials and Methods: In this double-blinded randomized controlled trial, 40 age-matched patients with confirmed Erythrasma diagnosis were divided into two equal groups; one treated with topical 1% Sertaconazole and other with topical 1% Clotrimazole. Then, the clinical features of Erythrasma were monitored for two weeks (Baseline, day 7 and day 14) and compared. Data were analyzed using SPSS v16 Statistics software. Results: In day 7, in Clotrimazole group, reduction in erythema and pigmentation were more prominent in comparison to Sertaconazole group (p=0.02 and p=0.005, respectively), but there was no difference considering scaling reduction between groups. In day 14, in terms of erythema reduction Clotrimazole group performed better compared to Sertaconazole group (p=0.04), this difference was not significant pigmentation and scaling reduction. Both groups had a significant reduction in Erythrasma symptoms during their treatment period (p<0.001). Conclusion: Regarding the results, both Clotrimazole and Sertaconazole are effective medications for Erythrasma treatment, but Clotrimazole has a faster recovery process in comparison to Sertaconazole, but no significant difference is observed in outcomes after two weeks of treatment.

Keywords:

Erythropoietin , Ischemic Brain Damage , Carotid Artery Clamp , Rat.